Literature DB >> 25071177

FGF2 is a target and a trigger of epigenetic mechanisms associated with differences in emotionality: partnership with H3K9me3.

Sraboni Chaudhury1, Elyse L Aurbach2, Vikram Sharma2, Peter Blandino2, Cortney A Turner2, Stanley J Watson3, Huda Akil4.   

Abstract

Posttranslational modifications of histone tails in chromatin template can result from environmental experiences such as stress and substance abuse. However, the role of epigenetic modifications as potential predisposing factors in affective behavior is less well established. To address this question, we used our selectively bred lines of high responder (bHR) and low responder (bLR) rats that show profound and stable differences in affective responses, with bLRs being prone to anxiety- and depression-like behavior and bHRs prone to addictive behavior. We first asked whether these phenotypes are associated with basal differences in epigenetic profiles. Our results reveal broad between-group differences in basal levels of trimethylated histone protein H3 at lysine 9 (H3K9me3) in hippocampus (HC), amygdala, and nucleus accumbens. Moreover, levels of association of H3K9me3 at Glucocorticoid Receptor (GR) and Fibroblast growth Factor 2 (FGF2) promoters differ reciprocally between bHRs and bLRs in these regions, consistent with these genes' opposing levels of expression and roles in modulating anxiety behavior. Importantly, this basal epigenetic pattern is modifiable by FGF2, a factor that modulates anxiety behavior. Thus, early-life FGF2, which decreases anxiety, altered the levels of H3K9me3 and its binding at FGF2 and GR promoters of bLRs rendering them more similar to bHRs. Conversely, knockdown of HC FGF2 altered both anxiety behavior and levels of H3K9me3 in bHRs, rendering them more bLR-like. These findings implicate FGF2 as a modifier of epigenetic mechanisms associated with emotional responsiveness, and point to H3K9me3 as a key player in the regulation of affective vulnerability.

Entities:  

Keywords:  H3K9me2; H4K20me3; MR; plus maze

Mesh:

Substances:

Year:  2014        PMID: 25071177      PMCID: PMC4136576          DOI: 10.1073/pnas.1411618111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  The three-hit concept of vulnerability and resilience: toward understanding adaptation to early-life adversity outcome.

Authors:  Nikolaos P Daskalakis; Rosemary C Bagot; Karen J Parker; Christiaan H Vinkers; E R de Kloet
Journal:  Psychoneuroendocrinology       Date:  2013-07-07       Impact factor: 4.905

2.  Toward a novel endogenous anxiolytic factor, fibroblast growth factor 2.

Authors:  Natalina Salmaso; Flora M Vaccarino
Journal:  Biol Psychiatry       Date:  2011-03-15       Impact factor: 13.382

3.  Psychological stress increases histone H3 phosphorylation in adult dentate gyrus granule neurons: involvement in a glucocorticoid receptor-dependent behavioural response.

Authors:  Alicia Bilang-Bleuel; Sabine Ulbricht; Yalini Chandramohan; Sonja De Carli; Susanne K Droste; Johannes M H M Reul
Journal:  Eur J Neurosci       Date:  2005-10       Impact factor: 3.386

Review 4.  DNA methylation and the formation of heterochromatin in Neurospora crassa.

Authors:  M R Rountree; E U Selker
Journal:  Heredity (Edinb)       Date:  2010-04-21       Impact factor: 3.821

5.  CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum.

Authors:  Amir A Levine; Zhonghui Guan; Angel Barco; Shiqin Xu; Eric R Kandel; James H Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-27       Impact factor: 11.205

6.  Novelty-seeking behavior predicts vulnerability in a rodent model of depression.

Authors:  Kristen A Stedenfeld; Sarah M Clinton; Ilan A Kerman; Huda Akil; Stanley J Watson; Alan F Sved
Journal:  Physiol Behav       Date:  2011-02-12

7.  Cocaine dynamically regulates heterochromatin and repetitive element unsilencing in nucleus accumbens.

Authors:  Ian Maze; Jian Feng; Matthew B Wilkinson; HaoSheng Sun; Li Shen; Eric J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

8.  Dysregulation of the fibroblast growth factor system in major depression.

Authors:  S J Evans; P V Choudary; C R Neal; J Z Li; M P Vawter; H Tomita; J F Lopez; R C Thompson; F Meng; J D Stead; D M Walsh; R M Myers; W E Bunney; S J Watson; E G Jones; H Akil
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-13       Impact factor: 11.205

Review 9.  Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse.

Authors:  Karen Brami-Cherrier; Emmanuel Roze; Jean-Antoine Girault; Sandrine Betuing; Jocelyne Caboche
Journal:  J Neurochem       Date:  2009-01-12       Impact factor: 5.372

10.  Single prolonged stress enhances hippocampal glucocorticoid receptor and phosphorylated protein kinase B levels.

Authors:  Andrew L Eagle; Dayan Knox; Megan M Roberts; Kostika Mulo; Israel Liberzon; Matthew P Galloway; Shane A Perrine
Journal:  Neurosci Res       Date:  2012-11-29       Impact factor: 3.304

View more
  21 in total

1.  Effects of early-life FGF2 on ultrasonic vocalizations (USVs) and the mu-opioid receptor in male Sprague-Dawley rats selectively-bred for differences in their response to novelty.

Authors:  Cortney A Turner; Megan H Hagenauer; Elyse L Aurbach; Pamela M Maras; Chelsea L Fournier; Peter Blandino; Rikav B Chauhan; Jaak Panksepp; Stanley J Watson; Huda Akil
Journal:  Brain Res       Date:  2019-03-14       Impact factor: 3.252

2.  Understanding Addiction Using Animal Models.

Authors:  Brittany N Kuhn; Peter W Kalivas; Ana-Clara Bobadilla
Journal:  Front Behav Neurosci       Date:  2019-11-29       Impact factor: 3.558

Review 3.  Revisiting the Stress Concept: Implications for Affective Disorders.

Authors:  Bruce S McEwen; Huda Akil
Journal:  J Neurosci       Date:  2020-01-02       Impact factor: 6.167

4.  Fibroblast growth factor 9 is a novel modulator of negative affect.

Authors:  Elyse L Aurbach; Edny Gula Inui; Cortney A Turner; Megan H Hagenauer; Katherine E Prater; Jun Z Li; Devin Absher; Najmul Shah; Peter Blandino; William E Bunney; Richard M Myers; Jack D Barchas; Alan F Schatzberg; Stanley J Watson; Huda Akil
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

5.  Fibroblast growth factor 2 alters the oxytocin receptor in a developmental model of anxiety-like behavior in male rat pups.

Authors:  Yoav Litvin; Cortney A Turner; Mariel B Rios; Pamela M Maras; Sraboni Chaudhury; Miriam R Baker; Peter Blandino; Stanley J Watson; Huda Akil; Bruce McEwen
Journal:  Horm Behav       Date:  2016-09-28       Impact factor: 3.587

6.  Fibroblast Growth Factor 2 Sits at the Interface of Stress and Anxiety.

Authors:  Cortney A Turner; Stanley J Watson; Huda Akil
Journal:  Biol Psychiatry       Date:  2016-09-15       Impact factor: 13.382

Review 7.  Don't worry; be informed about the epigenetics of anxiety.

Authors:  Steven J Nieto; Michelle A Patriquin; David A Nielsen; Therese A Kosten
Journal:  Pharmacol Biochem Behav       Date:  2016-05-14       Impact factor: 3.533

8.  Deletion of fibroblast growth factor 22 (FGF22) causes a depression-like phenotype in adult mice.

Authors:  Aislinn J Williams; Patricia Yee; Mitchell C Smith; Geoffrey G Murphy; Hisashi Umemori
Journal:  Behav Brain Res       Date:  2016-03-29       Impact factor: 3.332

Review 9.  Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders.

Authors:  Cortney A Turner; Emine Eren-Koçak; Edny G Inui; Stanley J Watson; Huda Akil
Journal:  Semin Cell Dev Biol       Date:  2015-10-23       Impact factor: 7.727

10.  Genetic background and epigenetic modifications in the core of the nucleus accumbens predict addiction-like behavior in a rat model.

Authors:  Shelly B Flagel; Sraboni Chaudhury; Maria Waselus; Rebeca Kelly; Salima Sewani; Sarah M Clinton; Robert C Thompson; Stanley J Watson; Huda Akil
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.